Intas Pharmaceuticals completed the acquisition of Udenyca from Coherus for $558m.

Intas Pharmaceuticals, an Indian multinational pharmaceutical company, completed the acquisition of Udenyca, a pharmaceutical compan, from Coherus, a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies, for $558m. "We are energized by this addition to Accord BioPharma's portfolio because it exemplifies our commitment to improving patient access to high-quality treatments that effectively meet the needs of both patients and healthcare providers. We are pleased with the successful completion of this agreement and are excited about the future opportunities it brings for Accord BioPharma in the US market," Binish Chudgar, Intas Pharmaceuticals Executive Chairman and Managing Director.